RS61608B1 - N- (6 - ((2r, 3s) -3,4-dihidroksibutan-2-iloksi) -2- (4-fluorobenziltio) pirimidin-4-il) -3- metilazetidin-1-sulfonamid kao modulator receptora hemokina - Google Patents
N- (6 - ((2r, 3s) -3,4-dihidroksibutan-2-iloksi) -2- (4-fluorobenziltio) pirimidin-4-il) -3- metilazetidin-1-sulfonamid kao modulator receptora hemokinaInfo
- Publication number
- RS61608B1 RS61608B1 RS20210370A RSP20210370A RS61608B1 RS 61608 B1 RS61608 B1 RS 61608B1 RS 20210370 A RS20210370 A RS 20210370A RS P20210370 A RSP20210370 A RS P20210370A RS 61608 B1 RS61608 B1 RS 61608B1
- Authority
- RS
- Serbia
- Prior art keywords
- dihydroxybutan
- fluorobenzylthio
- methylazetidine
- yloxy
- pyrimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/20—Free hydroxyl or mercaptan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/78—Benzoic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161506737P | 2011-07-12 | 2011-07-12 | |
EP16202983.9A EP3255043B1 (en) | 2011-07-12 | 2012-07-10 | N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3- methylazetidine-1-sulfonamide as chemokine receptor modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
RS61608B1 true RS61608B1 (sr) | 2021-04-29 |
Family
ID=46513787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20210370A RS61608B1 (sr) | 2011-07-12 | 2012-07-10 | N- (6 - ((2r, 3s) -3,4-dihidroksibutan-2-iloksi) -2- (4-fluorobenziltio) pirimidin-4-il) -3- metilazetidin-1-sulfonamid kao modulator receptora hemokina |
Country Status (37)
Country | Link |
---|---|
US (3) | US8735413B2 (sr) |
EP (2) | EP2731945A1 (sr) |
JP (2) | JP6006308B2 (sr) |
KR (1) | KR101946664B1 (sr) |
CN (1) | CN103781781B (sr) |
AR (2) | AR087168A1 (sr) |
AU (2) | AU2012282316B2 (sr) |
BR (1) | BR112014000636B1 (sr) |
CA (1) | CA2841859C (sr) |
CL (1) | CL2014000079A1 (sr) |
CO (1) | CO6852072A2 (sr) |
CR (1) | CR20140007A (sr) |
CU (2) | CU24292B1 (sr) |
CY (1) | CY1124329T1 (sr) |
DK (1) | DK3255043T3 (sr) |
DO (1) | DOP2013000308A (sr) |
EA (1) | EA027821B1 (sr) |
EC (1) | ECSP14013130A (sr) |
ES (1) | ES2861927T3 (sr) |
HK (1) | HK1245779A1 (sr) |
HR (1) | HRP20210413T1 (sr) |
HU (1) | HUE053703T2 (sr) |
IL (1) | IL230398A (sr) |
LT (1) | LT3255043T (sr) |
MX (2) | MX342874B (sr) |
MY (1) | MY180039A (sr) |
NI (1) | NI201400002A (sr) |
PE (2) | PE20181069A1 (sr) |
PL (1) | PL3255043T3 (sr) |
PT (1) | PT3255043T (sr) |
RS (1) | RS61608B1 (sr) |
SG (1) | SG10201605619XA (sr) |
SI (1) | SI3255043T1 (sr) |
TW (2) | TWI659026B (sr) |
UY (1) | UY34191A (sr) |
WO (1) | WO2013008002A1 (sr) |
ZA (1) | ZA201401059B (sr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103097377A (zh) | 2010-07-13 | 2013-05-08 | 阿斯利康(瑞典)有限公司 | N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]-1-氮杂环丁烷磺酰胺的新晶形 |
ES2861927T3 (es) * | 2011-07-12 | 2021-10-06 | Astrazeneca Ab | N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina |
EP2740458B1 (en) * | 2012-12-06 | 2016-08-03 | IP Gesellschaft für Management mbH | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide |
BR112018068393A2 (pt) * | 2016-03-11 | 2019-01-15 | Ardea Biosciences Inc | inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais |
JP2020533332A (ja) * | 2017-09-12 | 2020-11-19 | アルデア バイオサイエンシーズ インク. | 障害を処置するためのcxcr−2阻害剤 |
EP3983340B1 (en) * | 2019-06-12 | 2023-08-02 | Nouryon Chemicals International B.V. | Method for isolating carboxylic acid from an aqueous side stream |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3457278A (en) * | 1964-10-15 | 1969-07-22 | Geigy Chem Corp | Cyclopropyl-4-sulfanilamido-pyrimidines |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US6184225B1 (en) | 1996-02-13 | 2001-02-06 | Zeneca Limited | Quinazoline derivatives as VEGF inhibitors |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
FI981521A0 (fi) * | 1998-07-01 | 1998-07-01 | Orion Corp | Substituoidut beta-diketonit ja niiden käyttö |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
JP2003535078A (ja) | 2000-05-31 | 2003-11-25 | アストラゼネカ アクチボラグ | 血管損傷活性のあるインドール誘導体 |
EP1301498A1 (en) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as angiogenesis inhibitors |
BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
RU2408587C2 (ru) | 2004-08-24 | 2011-01-10 | Астразенека Аб | Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов |
GB0419235D0 (en) * | 2004-08-28 | 2004-09-29 | Astrazeneca Ab | Compounds |
PL1973884T3 (pl) * | 2006-01-19 | 2017-05-31 | Orchid Pharma Limited | Nowe związki heterocykliczne |
WO2008157273A1 (en) * | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
RU2011101661A (ru) | 2008-07-16 | 2012-08-27 | Астразенека Аб (Se) | Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний |
WO2010009994A2 (de) | 2008-07-25 | 2010-01-28 | Basf Se | 3-aminomethyl-1-cyclohexylamin und ein verfahren zu dessen herstellung |
CN103097377A (zh) * | 2010-07-13 | 2013-05-08 | 阿斯利康(瑞典)有限公司 | N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]-1-氮杂环丁烷磺酰胺的新晶形 |
ES2861927T3 (es) * | 2011-07-12 | 2021-10-06 | Astrazeneca Ab | N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina |
-
2012
- 2012-07-10 ES ES16202983T patent/ES2861927T3/es active Active
- 2012-07-10 WO PCT/GB2012/051620 patent/WO2013008002A1/en active Application Filing
- 2012-07-10 BR BR112014000636-9A patent/BR112014000636B1/pt active IP Right Grant
- 2012-07-10 PE PE2018000520A patent/PE20181069A1/es unknown
- 2012-07-10 SI SI201231899T patent/SI3255043T1/sl unknown
- 2012-07-10 EP EP12735323.3A patent/EP2731945A1/en not_active Withdrawn
- 2012-07-10 LT LTEP16202983.9T patent/LT3255043T/lt unknown
- 2012-07-10 CA CA2841859A patent/CA2841859C/en active Active
- 2012-07-10 RS RS20210370A patent/RS61608B1/sr unknown
- 2012-07-10 KR KR1020147000487A patent/KR101946664B1/ko active IP Right Grant
- 2012-07-10 DK DK16202983.9T patent/DK3255043T3/da active
- 2012-07-10 CU CUP2014000004A patent/CU24292B1/xx unknown
- 2012-07-10 EP EP16202983.9A patent/EP3255043B1/en active Active
- 2012-07-10 MY MYPI2014700061A patent/MY180039A/en unknown
- 2012-07-10 CN CN201280044385.0A patent/CN103781781B/zh active Active
- 2012-07-10 MX MX2013015085A patent/MX342874B/es active IP Right Grant
- 2012-07-10 PT PT162029839T patent/PT3255043T/pt unknown
- 2012-07-10 EA EA201490077A patent/EA027821B1/ru not_active IP Right Cessation
- 2012-07-10 HU HUE16202983A patent/HUE053703T2/hu unknown
- 2012-07-10 JP JP2014519625A patent/JP6006308B2/ja active Active
- 2012-07-10 PL PL16202983T patent/PL3255043T3/pl unknown
- 2012-07-10 MX MX2016000277A patent/MX353334B/es unknown
- 2012-07-10 PE PE2014000009A patent/PE20141944A1/es active IP Right Grant
- 2012-07-10 AU AU2012282316A patent/AU2012282316B2/en not_active Ceased
- 2012-07-10 SG SG10201605619XA patent/SG10201605619XA/en unknown
- 2012-07-11 TW TW106135796A patent/TWI659026B/zh not_active IP Right Cessation
- 2012-07-11 TW TW101124908A patent/TWI633098B/zh active
- 2012-07-11 UY UY0001034191A patent/UY34191A/es not_active Application Discontinuation
- 2012-07-11 US US13/546,444 patent/US8735413B2/en active Active
- 2012-07-12 AR ARP120102531A patent/AR087168A1/es not_active Application Discontinuation
-
2013
- 2013-12-17 DO DO2013000308A patent/DOP2013000308A/es unknown
-
2014
- 2014-01-09 NI NI201400002A patent/NI201400002A/es unknown
- 2014-01-09 IL IL230398A patent/IL230398A/en active IP Right Grant
- 2014-01-09 CR CR20140007A patent/CR20140007A/es unknown
- 2014-01-10 CL CL2014000079A patent/CL2014000079A1/es unknown
- 2014-01-10 CO CO14004182A patent/CO6852072A2/es active IP Right Grant
- 2014-01-10 EC ECSP14013130 patent/ECSP14013130A/es unknown
- 2014-02-11 ZA ZA2014/01059A patent/ZA201401059B/en unknown
- 2014-04-15 US US14/253,288 patent/US9221782B2/en not_active Expired - Fee Related
- 2014-11-03 HK HK18105226.5A patent/HK1245779A1/zh unknown
-
2015
- 2015-12-28 US US14/980,754 patent/US9975881B2/en active Active
-
2016
- 2016-06-10 CU CUP2016000083A patent/CU20160083A7/es unknown
- 2016-07-01 JP JP2016131785A patent/JP6261666B2/ja active Active
- 2016-10-12 AU AU2016244246A patent/AU2016244246B2/en not_active Ceased
-
2021
- 2021-03-12 HR HRP20210413TT patent/HRP20210413T1/hr unknown
- 2021-04-07 CY CY20211100296T patent/CY1124329T1/el unknown
-
2022
- 2022-01-21 AR ARP220100128A patent/AR124688A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL242278A0 (en) | Compounds 4)-n-fluoro-2-methoxy-5-nitrophenyl)pyrimidine-2-converted amine and their salts | |
HK1214499A1 (zh) | 穩定的低粘度抗體配製品 | |
AP2012006192A0 (en) | PyrroloÄ2,3-DÜ pyrimidine compounds. | |
HK1187905A1 (zh) | 作為激酶抑制劑的取代的嘧啶基-吡咯類活性劑 | |
HK1245779A1 (zh) | 作為趨化因子受體調節劑的n-(6-((2r,3s)-3,4-二羥基丁-2-基氧基)-2-(4-氟苄基硫基)嘧啶-4-基)-3-甲基氮雜環丁烷-1-磺酰胺 | |
BRPI1013760A2 (pt) | compostos anticâncer de amino pirimidina. | |
GB201012105D0 (en) | Novel pyrimidine compounds | |
IL230997A0 (en) | 10pde pyrimidine inhibitors | |
EP2670746A4 (en) | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | |
EP2860181A4 (en) | CONDENSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USES OF SAID COMPOUND | |
HK1206288A1 (en) | Capillary channel structure for dispense interface | |
HK1198741A1 (en) | New (trimethoxyphenylamino)pyrimidinyl formulations () | |
HK1259248A1 (zh) | 作為趨化因子受體調節劑的新的1,2-雙-磺醯胺衍生物 | |
PL2790695T3 (pl) | Kompozycja farmaceutyczna zawierająca (S)-2-(2-oksopirolidyn-1-ylo)butanamid | |
EP2744334A4 (en) | N- (5-fluoro-2 - ((4-methylbenzyl) oxy) pyrimidin-4-yl) benzamide derivatives | |
AU2012902979A0 (en) | Clip on Drink holder | |
AU2012904244A0 (en) | Neurotrophin-tyrosine kinase receptor signaling | |
AU2011905028A0 (en) | E-trakka equine stride length system | |
AU2011903361A0 (en) | Biopharmaceutical application for antiviral effects. |